STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Pancreatic cancer (PanCA) has a poor 5-year survival rate (<5%), necessitating novel therapeutic strategies.
• Nexrutine (Nx), derived from Phellodendron amurense, demonstrates anticancer effects in PanCA cells by inhibiting inflammatory pathways (STAT3/NFκB/Cox-2).
• Pancreatic tumors exhibit high oxidative stress and autophagic activity, suggesting these pathways as therapeutic targets.

Purpose of the Study:

• To investigate the effects of Nx on autophagy and reactive oxygen species (ROS) in pancreatic cancer.
• To explore the crosstalk between autophagy, ROS, and the STAT3 signaling pathway in Nx-treated PanCA cells.
• To evaluate the therapeutic potential of combining Nx with autophagy inhibitors.

Main Methods:

• Cell culture of human pancreatic cancer cells.
• Treatment with Nexrutine (Nx), autophagy inhibitors, and STAT3 inhibitors (genetic/pharmacological).
• Analysis of autophagy markers (LC3-II), ROS generation, cell proliferation, and apoptosis.
• Combination index analysis for synergistic effects.

Main Results:

• Nx inhibits autophagy and decreases ROS generation in pancreatic cancer cells.
• Pharmacological inhibition of autophagy reduces ROS and proliferation, without significantly impacting apoptosis.
• Combination of Nx with a late-stage autophagy inhibitor showed moderate synergistic to additive effects.
• STAT3 inactivation reduced autophagy markers, suggesting STAT3's role in regulating autophagy transcription.
• Nx-mediated anti-cancer effects involve the STAT3/LC3/ROS pathway.

Conclusions:

• Nexrutine modulates autophagy and ROS, contributing to its anti-pancreatic cancer activity.
• STAT3 signaling is implicated in the regulation of autophagy and its crosstalk with ROS in pancreatic cancer.
• Nx represents a potential therapeutic agent for pancreatic cancer, possibly enhanced by combination therapies targeting autophagy.